IVBT Stock Overview
Does not have significant operations. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Innovation1 Biotech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0008 |
52 Week High | US$1.20 |
52 Week Low | US$0.0008 |
Beta | 5.1 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -99.56% |
33 Year Change | -99.94% |
5 Year Change | -99.97% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
IVBT | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 2.6% | 0.5% |
1Y | -99.6% | 13.1% | 30.7% |
Return vs Industry: IVBT underperformed the US Pharmaceuticals industry which returned 26.5% over the past year.
Return vs Market: IVBT underperformed the US Market which returned 22% over the past year.
Price Volatility
IVBT volatility | |
---|---|
IVBT Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IVBT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IVBT's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 1 | Rick Pierce | www.innovation1bio.com |
Innovation1 Biotech Inc., does not have significant operations. Previously, it was focused on the development of modified schedule 1 molecules of botanical origin in the United States. The company was founded in 2014 and is based in Somerville, Massachusetts.
Innovation1 Biotech Inc. Fundamentals Summary
IVBT fundamental statistics | |
---|---|
Market cap | US$17.98k |
Earnings (TTM) | -US$14.08m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IVBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IVBT income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$14.08m |
Earnings | -US$14.08m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.63 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -6.7% |
How did IVBT perform over the long term?
See historical performance and comparison